Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
2.720
+0.110 (4.21%)
At close: Feb 19, 2026, 4:00 PM EST
2.727
+0.007 (0.24%)
After-hours: Feb 19, 2026, 5:05 PM EST
Acumen Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
61
Market Cap
164.76M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 1.44M | -261.00K | -15.38% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sangamo Therapeutics | 32.88M |
| Zentalis Pharmaceuticals | 26.87M |
| ProQR Therapeutics | 18.86M |
| Whitehawk Therapeutics | 14.38M |
| Caribou Biosciences | 9.30M |
| Rani Therapeutics Holdings | 1.20M |
| Adagene | 103.20K |
ABOS News
- 3 months ago - Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Acumen Pharmaceuticals, Inc. (ABOS) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 6 months ago - Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 7 months ago - Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025 - GlobeNewsWire
- 7 months ago - JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform - Business Wire
- 8 months ago - Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025 - GlobeNewsWire